Roman Reindl-Schwaighofer
Overview
Explore the profile of Roman Reindl-Schwaighofer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
80
Citations
989
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hochreiter B, Lindner C, Postl M, Hunyadi-Gulyas E, Darula Z, Domenig O, et al.
Int J Mol Sci
. 2025 Jan;
26(2.
PMID: 39859396
Drug development for human disease relies on preclinical model systems such as human cell cultures and animal experiments before therapeutic treatments can ultimately be tested on humans in clinical studies....
2.
Krenn K, Kraft F, Mandroiu L, Tretter V, Reindl-Schwaighofer R, Clement T, et al.
Ann Intensive Care
. 2025 Jan;
15(1):10.
PMID: 39821855
Background: Acute respiratory distress syndrome (ARDS) associated with coronavirus infectious disease (COVID)-19 has been a challenge in intensive care medicine for the past three years. Dysregulation of the renin-angiotensin system...
3.
Reindl-Schwaighofer R, Heinzel A, Raab L, Strassl R, Herz C, Regele F, et al.
EBioMedicine
. 2024 Oct;
109:105417.
PMID: 39442367
Background: The response to severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) vaccination is severely impaired in patients on maintenance immunosuppression after kidney transplantation. Methods: We conducted a prospective cohort...
4.
David A, Heinzel A, Kammer M, Aschauer C, Reindl-Schwaighofer R, Hu K, et al.
EBioMedicine
. 2024 Jul;
106:105239.
PMID: 38996766
Background: Induction of donor-specific tolerance is a promising approach to achieve long-term graft patency in transplantation with little to no maintenance immunosuppression. Changes to the recipient's T cell receptor (TCR)...
5.
Ernst A, Regele H, Chatzikyrkou C, Dendooven A, Turkevi-Nagy S, Tieken I, et al.
Nephrol Dial Transplant
. 2024 Apr;
40(1):83-108.
PMID: 38632055
Background: The decision to accept or discard the increasingly rare and marginal brain-dead donor kidneys in Eurotransplant (ET) countries has to be made without solid evidence. Thus, we developed and...
6.
Albert M, Uranga-Murillo I, Arias M, de Miguel D, Pena N, Montinaro A, et al.
Cell Death Differ
. 2024 Mar;
31(5):544-557.
PMID: 38514848
The dysregulated immune response and inflammation resulting in severe COVID-19 are still incompletely understood. Having recently determined that aberrant death-ligand-induced cell death can cause lethal inflammation, we hypothesized that this...
7.
Reindl-Schwaighofer R, Heinzel A, Oberbauer R
Clin Kidney J
. 2024 Mar;
17(3):sfad242.
PMID: 38495221
No abstract available.
8.
Hullekes F, Uffing A, Verhoeff R, Seeger H, Moos S, Mansur J, et al.
Am J Transplant
. 2024 Feb;
24(6):1016-1026.
PMID: 38341027
Membranous nephropathy (MN) is a leading cause of kidney failure worldwide and frequently recurs after transplant. Available data originated from small retrospective cohort studies or registry analyses; therefore, uncertainties remain...
9.
Jabbour R, Heinzel A, Reindl-Schwaighofer R, Gregorich M, Regele H, Kozakowski N, et al.
Nephrol Dial Transplant
. 2023 Nov;
39(5):808-817.
PMID: 37960919
Background: Early progression of chronic histologic lesions in kidney allografts represents the main finding in graft attrition. The objective of this retrospective cohort study was to elucidate whether HLA histocompatibility...
10.
Rathkolb V, Traugott M, Heinzel A, Poglitsch M, Aberle J, Eskandary F, et al.
iScience
. 2023 Oct;
26(11):108146.
PMID: 37867935
Despite the similar clinical outcomes after renin-angiotensin system (RAS) inhibitor (RASi) continuation or withdrawal in COVID-19, the effects on angiotensin-converting enzyme 2 (ACE2) and RAS metabolites remain unclear. In a...